World Gastroenterology Organisation Global Guidelines

LaBrecque, Douglas R.; Abbas, Zaigham; Anania, Frank A.; Ferenci, Péter; Khan, Aamir Ghafoor; Goh, Khean‐Lee; Salehiniya, Hamid; Isakov, Vasily; Lizarzábal, Maribel; Peñaranda, Manuel M.; Ramos, Juan Francisco Rivera; Sarin, Shiv Kumar; Stimac, Davor; Thomson, A. B. R.; Umar, Muhammed; Krabshuis, Justus; LeMair, Anton

doi:10.1097/mcg.0000000000000116

Cited by 338 publications

(209 citation statements)

References 11 publications

Supporting

Mentioning

205

Contrasting

Unclassified

Order By: Relevance

“…Hepatic steatosis transpires on account of repeated liver injury and the initiation of liver inflammation [2]. This can progress to non-alcoholic steatohepatitis (NASH), liver fibrosis and cirrhosis, as well as hepatocellular carcinoma [1,[3][4][5]. The pathophysiology of NALFD is multifactorial and is believed to result from 'multiple hits hypothesis' incorporating diverse genetic and environmental processes [6,7].…”

Section: Introductionmentioning

confidence: 99%

Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP)

Papapostoli

Lammert

Stokes

2016

JGLD

View full text Add to dashboard Cite

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. A meta-analysis has confirmed decreased serum 25-hydroxyvitamin D levels in NAFLD patients. This intervention study investigates whether vitamin D correction ameliorates hepatic steatosis. Methods: We prospectively recruited 40 patients from an outpatient liver clinic with vitamin D deficiency (serum 25-hydroxyvitamin D < 20 ng/ml). Controlled attenuation parameter (CAP) during transient elastography quantified hepatic steatosis. Patients with significant liver fat accumulation were included, which was defined by a CAP value ≥ 280 dB/m. Patients received 20,000 IU vitamin D/week for six months, while vitamin D status, liver function tests (LFTs), CAP and body composition were monitored. Results: The cohort comprised 47.5% women (age 54.9 ± 12.1 years; BMI 29.5 ± 3.0 kg/m2). Mean serum vitamin D level was 11.8 ± 4.8 ng/ml. CAP decreased significantly from baseline (330 ± 32 vs. 307 ± 41 dB/m) during supplementation (P = 0.007). A mean CAP reduction relative to baseline was demonstrated at four weeks and three and six months: -5.3 ± 13.8%; -6.0 ± 14.6% and -6.4 ± 13.0%, respectively. During these time points, restoration of serum vitamin D levels was observed (34.6 ± 12.9, 36.3 ± 10.2, 34.8 ± 9.8 ng/ml; P < 0.0001). Liver function tests and body composition remained unchanged. Conclusions: Hepatic steatosis, as assessed by CAP, significantly improves after only 4 weeks of vitamin D correction. Hepatic steatosis is a dynamic process, that can be monitored in the short-term using such non-invasive methods. Abbreviations: ALT: alanine aminotransferase; ANOVA: analysis of variance; AP: alkaline phosphatase; AST: aspartate aminotransferase; CAP: controlled attenuation parameter; CRP: C-reactive protein; FFA: free fatty acids; γ-GT: gamma-glutamyl transpeptidase; ITT: intention-to-treat; LFT: liver function test; LSM: liver stiffness measurement; NAFLD: non-alcoholic fatty liver disease; PPAR-γ: peroxisome proliferator-activated receptor gamma; PP: per protocol; PTH: parathyroid hormone; VDR: vitamin D receptor

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP)

Papapostoli

Lammert

Stokes

2016

JGLD

View full text Add to dashboard Cite

show abstract

“…It is estimated that over 1 billion adults have overweight or obesity (1). Obesity (body mass index (BMI) > 30 kg/m 2 ) or morbid obesity (BMI > 40 or 35 kg/m 2 with complications) affect normal function of different systems of the body such as cardiovascular, respiratory, and endovascular systems (2,3).…”

Section: Backgroundsmentioning

confidence: 99%

“…Obesity (body mass index (BMI) > 30 kg/m 2 ) or morbid obesity (BMI > 40 or 35 kg/m 2 with complications) affect normal function of different systems of the body such as cardiovascular, respiratory, and endovascular systems (2,3). Obesity is correlated with metabolic syndrome (a syndrome known with trunk obesity, high triglyceride level, decrease in high-density lipoprotein (HDL), hypertension, and hyperglycemia) and its liver complication; i e, non-alcoholic fatty liver disease (NAFLD) (1). Fatty liver includes a range of different liver diseases, from simple steatosis to steatohepatitis.…”

Section: Backgroundsmentioning

confidence: 99%

Predictive Factors of Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Undergoing Bariatric Surgery

et al. 2017

View full text Add to dashboard Cite

Background and Objectives: Obesity is one of the most health-threatening phenomena. It is estimated that over 1 billion adults have overweight or obesity. The current study aimed at presenting a detailed account of the findings that attempted to predict the severity of fatty liver disease and its sequelae, including non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, by correlating biopsy results with liver function tests and various metabolic markers of laboratory results in patients with morbid obesity.

show abstract

“…A EHNA está presente em cerca de 2-3% da população em geral e entre 10-20% da população com DHGNA. (Tabela 1) (LaBrecque et al, 2014;Angulo, 2011Angulo, , 2002Matteoni et al, 1999;Clark, 2006 Hashimoto et al, 2015;Watanabe et al, 2015) Como manifestação hepática da Síndrome Metabólica, a DHGNA/EHNA está associada a obesidade, resistência insulínica e Diabetes, Dislipidemia e Hipertensão, doenças relacionadas ao estilo de vida. E possui outras causas e fatores de risco, além do consumo calórico excessivo e baixo gasto de energia, como doenças endócrinas, desnutrição grave e efeitos colaterais de medicamentos (Tabela 2) (Watanabe et al, 2015;LaBrecque et al, 2014).…”

Section: A Organização Mundial De Saúde (Oms) Instituiu Em 2010 O DIunclassified

“…( LaBrecque et al, 2014) Como a DHGNA é considerada um espectro de condições clínico-patológicas, a biópsia de fígado permanece considerada o padrão outro para o diagnóstico definitivo, apesar da dificuldade, custo e potenciais riscos Takahashi e Fukusato, 2014, Schattenberg e Galle, 2010 et al, 1998, Zhou et al, 2005. Entretanto, são extremamente caros (Manneras et al, 2007, Walters et al, 2012.…”

Section: A Organização Mundial De Saúde (Oms) Instituiu Em 2010 O DIunclassified

Análise metabolômica e histomorfométrica do fígado de ratas adultas em modelo experimental da síndrome dos ovários policísticos induzida por exposição neonatal a esteroides sexuais

Anzai¹

View full text Add to dashboard Cite

World Gastroenterology Organisation Global Guidelines

Cited by 338 publications

References 11 publications

Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP)

Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP)

Predictive Factors of Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Undergoing Bariatric Surgery

Análise metabolômica e histomorfométrica do fígado de ratas adultas em modelo experimental da síndrome dos ovários policísticos induzida por exposição neonatal a esteroides sexuais

Contact Info

Product

Resources

About